Cantor Fitzgerald Reiterates Overweight on Artiva Biotherapeutics, Maintains $40 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 82.3%

Neg 0% Neu 82.3% Pos 0%

Cantor Fitzgerald analyst Josh Schimmer reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Overweight and maintains $40 price target.